DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Nafamostat
Nafamostat
Empirical Treatment and Prevention of COVID-19
Safety and Tolerability of Nafamostat Mesilate And
Nafamostat Mesilate Improves Function Recovery After Stroke By
Coagulation Factors Directly Cleave SARS-Cov-2 Spike and Enhance Viral Entry
Jp Xvii the Japanese Pharmacopoeia
New Trends, Advantages and Disadvantages in Anticoagulation and Coating Methods Used in Extracorporeal Life Support Devices
Overview of Planned Or Ongoing Studies of Drugs for the Treatment of COVID-19
Nafamostat-Interferon-Alpha Combination Suppresses
Successful Conservative Treatment for Massive Uterine Bleeding with Non
Antithrombotic Therapy in COVID-19: Systematic Summary of Ongoing Or Completed Randomized Trials
Circulating Activated Protein C Levels Are Not Increased in Septic Patients
RCR05: Nafamostat
TMPRSS2 Inhibitors, Bromhexine, Aprotinin, Camostat and Nafamostat As Potential Treatments for COVID-19
The Anticoagulant Nafamostat Potently Inhibits SARS-Cov-2 Infection in Vitro: an Existing Drug with Multiple Possible Therapeutic Effects
Stembook 2018.Pdf
Comparative Analysis of Three Machine-Learning Techniques and Conventional Techniques for Predicting Sepsis-Induced Coagulopathy Progression
Anti-Tumor Effect by Inhibition of NF-Κb Activation Using Nafamostat Mesilate for Pancreatic Cancer in a Mouse Model
File Download
Top View
Homology Modeling of TMPRSS2 Yields Candidate Drugs That May Inhibit Entry of SARS-Cov-2 Into
Eunethta Joint Action 3 WP4 NAFAMOSTAT for the TREATMENT of COVID-19
Marzec 2020 3 Felieton Redakcji Felieton Redakcji
Nafamostat Mesilate Attenuates Neuronal Damage in a Rat Model Of
Potential of Heparin and Nafamostat Combination Therapy for COVID‐19
Use of Rivaroxaban for the Effective Management of Disseminated Intravascular Coagulation Associated with Abdominal Aortic Aneurysm
New Therapeutic Options for Patients with Sepsis and Disseminated Intravascular Coagulation
Nafamostat Mesylate Improved Survival Outcomes of Sepsis Patients Who Underwent Blood Purification: a Nationwide Registry Study in Japan
COVID-19: Predicting Inhibition of Repurposed Drugs for SARS-Cov-2 Viral Activity and Cellular Entry Clifford Fong
Download (Accessed on 27 June 2020)
(12) United States Patent (Io) Patent No.: US 9,526,824 B2 Ferrari Et Al
Use of Nafamostat Mesilate As an Anticoagulant During Extracorporeal Membrane Oxygenation
Nafamostat–Interferon-Α Combination Suppresses SARS-Cov-2 Infection in Vitro and in Vivo by Cooperatively Targeting Host TMPRSS2
022200Orig1s000
Downloaded from GEO (GSE68820)
Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds S
Nafamostat Mesilate, a Potent Serine Protease Inhibitor, Inhibits Airway
Regular Article Involvement of Human Blood Arylesterases and Liver Microsomal Carboxylesterases in Nafamostat Hydrolysis
Nafamostat-Interferon-Alpha Combination Suppresses
Inflammation and Thrombosis in Patients with COVID-19: a Prothrombotic and Inflammatory Disease Caused by SARS Coronavirus-2
COVID-19 Nafamostat Observational Study in Japan: Preliminary Report
Harmonized Tariff Schedule of the United States (2006) (Rev
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Nafamostat Reduces Systemic in Ammation in TLR7-Mediated Virus
The Anticoagulant Nafamostat Potently Inhibits SARS-Cov-2 S
A Review of the Possibility of Nafamostat Mesylate in COVID-19 Treatment
Inflammation and Coagulation: Implications for the Septic Patient
Harmonized Tariff Schedule of the United States (2003) -- Supplement 1 Annotated for Statistical Reporting Purposes
Thrombomodulin in Disseminated Intravascular Coagulation and Other
Nafamostat and Sepimostat Identified As Novel Neuroprotective Agents Via
Assessment of Evidence for COVID-19-Related Treatments
Recent Randomized Trials of Antithrombotic Therapy for Patients with COVID-19 JACC State-Of-The-Art Review
Recent Randomized Trials of Antithrombotic Therapy for Patients with COVID-19 JACC State-Of-The-Art Review
Coagulation Factors Directly Cleave SARS-Cov-2 Spike and Enhance Viral Entry
Sales & Marketing
T-Cell Activation-Inhibitory Assay to Screen Caloric Restriction Mimetics
Available Drugs and Supplements for Rapid Deployment for Treatment of COVID-19
WO 2012/123502 Al 20 September 2012 (20.09.2012) P O P C T